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Abstract
OBJECTIVES: This study reports a series of pitfalls, premature failures and explantations of the third-generation Freedom SOLO (FS) bovine
pericardial stentless valve.
METHODS: A total of 149 patients underwent aortic valve replacement using the FS. Follow-up was 100% complete with an average obser-
vation time of 5.5 ± 2.3 years (maximum 8.7 years) and a total of 825 patient-years. Following intraoperative documentation, all explanted
valve prostheses underwent histological examination.
RESULTS: Freedom from structural valve deterioration (SVD) at 5, 6, 7, 8 and 9 years was 92, 88, 80, 70 and 62%, respectively. Fourteen
prostheses required explantation due to valve-independent dysfunction (n = 5; i.e. thrombus formation, oversizing, aortic dilatation, endo-
carditis and suture dehiscence) or valve-dependent failure (acute leaﬂet tears, n = 4 and severe stenosis, n = 5). Thus, freedom from ex-
plantation at 5, 6, 7, 8 and 9 years was 95, 94, 91, 81 and 72%, respectively. An acute vertical tear along the non-coronary/right coronary
commissure to the base occurred at a mean of 6.0 years (range 4.3–7.3 years) and affected size 25 and 27 prostheses exclusively. Four FS
required explantation after a mean of 7.5 years (range 7.0–8.3 years) due to severe functional stenosis and gross calciﬁcation that included
the entire aortic root.
CONCLUSIONS: The FS stentless valve is safe to implant and shows satisfying mid-term results in our single institution experience.
Freedom from SVD and explantation decreased markedly after only 6–7 years, so that patients with FS require close observation and
follow-up. Exact sizing, symmetric positioning and observing patient limitations are crucial for optimal outcome.
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INTRODUCTION
Aortic valve replacement (AVR), usually with a biological pros-
thesis, is the treatment of choice for severe and symptomatic
aortic valve disease [1]. Stentless bioprostheses were introduced to
clinical practice as an attractive alternative to stented valves, with
excellent early clinical and haemodynamic results [2]. Freedom
from structural valve deterioration (SVD) and reoperation can be
inﬂuenced by the tissue structure (e.g. bovine versus porcine), the
design of the valve, its mechanical wear and stress absorption
properties; notably, chemical ﬁxation and the anticalciﬁcation
treatment are considered as key elements in valve manufacturing
aimed at enhancing valve durability [3].
The third-generation Freedom SOLO (FS) aortic valve bio-
prosthesis (Sorin Group, Saluggia, Italy), introduced in June 2004,
is made of two bovine pericardial sheets for supra-annular sub-
coronary implantation. The design is intended to preserve left
ventricular–aortic root coupling, which is thought to be essential
to protect aortic valve function by decreasing mechanical stress
on the leaﬂets and particularly the commissures, where structural
failure and calciﬁcation typically originate [4]. In addition, the FS
employs a unique manufacturing process to include homocysteic
acid (HCA) as an anticalciﬁcation treatment to bind and neutralize
free glutaraldehyde (GA) residues.
Our institution introduced the FS very early on. We [5]
and others [6] had reported a favourable early outcome with
excellent haemodynamic results for the FS. We now present,
however, our experience with valve-related and –non-related
failures and reoperations involving the FS after up to 8.7 years of
observation.
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METHODS
Patient population
Between January 2005 and November 2009, 149 patients (mean
age 73.6 ± 8.7 years, 68 [45.6%] female) in our department under-
went isolated (n = 75) or combined (n = 74) AVR with the FS valve.
The decision to use the FS stentless valve or an alternative conven-
tional stented prosthesis was at the surgeon’s discretion in accordance
with the patient’s wishes. The FS stentless valve was not considered
suitable in cases with severe calciﬁcation of the supra-annular sinus.
The local ethics committee approved review of the data and patient
consent was waived for the retrospective analysis. The patients’ char-
acteristics are given in Table 1. One patient was operated on with
acute bacterial endocarditis, and 4 cases were redo procedures.
Twenty patients (13.4%) had a left ventricular ejection fraction of
≤40% at the time of surgery.
Surgical and postoperative management
AVR procedures were all performed under routine general anaes-
thesia and with median sternotomy, using standard cardiopulmon-
ary bypass and mild hypothermia (34°C). Cold blood cardioplegia
was routinely used for myocardial protection. Aortotomy was
performed 1 cm above the sinotubular junction (STJ). The dis-
eased valve was then excised and the annulus carefully decalciﬁed.
The FS valve was implanted without rinsing in the supra-annular
subcoronary position, with continuous suture lines using 4/0 prolene
monoﬁlament in the sinuses of Valsalva. In brief, the sutures started
at the base of each sinus and followed to the top of the commissures
ending in extra-aortic ﬁxation. Transoesophageal echocardiography
(TOE) was routinely performed intraoperatively before and after
AVR to assess and document prosthesis function. Patients with the FS
valve require no regular anticoagulation after hospital discharge.
Data collection and follow-up
Perioperative data were retrieved from our prospectively managed
institutional database (Dendrite Clinical Systems Ltd, Henley-
on-Thames, UK). All patients were routinely examined with trans-
thoracic echocardiography before hospital discharge, at 6 months
and yearly thereafter. Transvalvular pressure gradients and the ef-
fective oriﬁce area (EOA) were calculated using the modiﬁed Bernoulli
equation and the continuity equation, respectively. Mortality and
morbidity (rate of adverse events) were reported according to the
established guidelines [7]. These guidelines deﬁne structural valve
deterioration (SVD) as change in function or deterioration of an
operated valve resulting from an intrinsic abnormality of the valve
that causes stenosis or regurgitation, exclusive of infection or throm-
bosis. SVD includes wear, fracture, poppet escape, calciﬁcation,
leaﬂet tear, stent creep and suture line disruption of an operated
valve [7]. Clinical status and adverse events were carefully assessed
at each visit or by consultation with the referring physician. The
follow-up was 100% complete with a cumulative total observation
of 825 patient-years (mean 5.5 ± 2.3 years [maximum 8.7 years]).
Histology
Following intraoperative photodocumentation, all explanted valve
prostheses were immediately ﬁxed in 10% neutral-buffered formalin
solution for at least 24 h. The valves were then processed in their en-
tirety by standard procedures, embedded in parafﬁn, decalciﬁed as
needed, cut into 3 µm sections and stained with haematoxylin and
eosin as well as Elastica van Gieson for histological examination.
Statistical analysis
Probabilities of freedom from death and freedom from explant-
ation for SVD were estimated by Kaplan–Meier actuarial analysis.
Demographic data are summarized by mean and shown with
standard deviation for continuous variables and by percentages
for categorical variables. All statistical analyses were performed
using the Stata statistical software package 12.0 (SPSS, Inc.,
Chicago, IL, USA). Outcome data are presented as operative mor-
tality, deﬁned as death from any cause during or after surgery
within 30 days if the patient was discharged, or within any interval
if the patient was not discharged [7].
RESULTS
Operative mortality was 2.7% (n = 4, all combined procedures) and
46 additional patients died during the observation period (44 of
Table 1: Patient characteristics
Number of patients 149
Age (years), mean ± SD 73.6 ± 8.7 (47.2–87.4)
Gender
Male (n, %) 81 (54.4)
Female (n, %) 68 (45.6)
BMI (kg/m2), mean ± SD 27.0 ± 6.5 (18.3–46.3)
BSA (Dubois, m2), mean ± SD 1.81 ± 0.29 (1.38–2.30)
Diabetes mellitus (n, %) 34 (22.8)
Arterial hypertension (n, %) 130 (87.2)
Renal impairment (n, %) 24 (16.1)
LVEF (%) 53.7 ± 12.3
NYHA class
I 14 (9.4)
II 62 (41.6)
III 54 (36.2)
IV 19 (12.8)
Aortic valve pathology
Stenosis 126 (84.6)
Regurgitation 10 (6.7)
Combined 13 (8.7)
Labelled valve size
#19 3 (2.0)
#21 28 (18.8)
#23 44 (29.5)
#25 39 (26.2)
#27 35 (23.5)
Combined procedures
CABG 79 (53.0)
MVR (DVR) 7 (4.7)
Othera 17 (11.4)
Values are n (%) or mean ± SD (range).
LVEF: left ventricular ejection fraction; MVR: mitral valve repair/
replacement; CABG: coronary artery bypass grafting; DVR: double valve
replacement.
aPersistent foramen ovale (PFO), tricuspid annuloplasty, ascendens tube
graft, ablation.
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them without reoperation, Fig. 1). Freedom from SVD at 5, 6, 7, 8
and 9 years was 92, 88, 80, 70 and 62%, respectively. Initial AVR
procedures were uneventful in 14 patients who later required
explantation of their FS prostheses for structural (n = 9) and non-
structural (n = 5) causes that are reported in more detail in Table 2.
Thus, freedom from explantation at 5, 6, 7, 8 and 9 years was 95,
94, 91, 81 and 72%, respectively.
Prosthesis replacement due to non-structural
dysfunction
Case 1. The patient was re-admitted with acute dyspnoea and
pulmonary oedema 5 months after combined CABG and AVR.
Coronary angiography showed patent bypass grafts, and TOE
showed normal morphology and function of the right (RCC) and
left coronary cusps (LCC). The non-coronary cusp (NCC), however,
was found immobile and adherent to the aortic wall resulting in
severe regurgitation with haemodynamic instability necessitating
reoperation. A large thrombotic adhesion on the NCC found
intraoperatively was shown by histology to cause the attachment
(Fig. 2), but there was no other structural damage. Despite an
uncomplicated replacement with a stented prosthesis and early
recovery, the patient suddenly fell into cardiac arrest on the
eighth postoperative day and died. Post hoc analysis of the TOE
records showed intercommissural distances of 24.8 mm (NCC),
27.3 mm (LCC) and 27.4 mm (RCC), respectively.
Case 2. Postoperative FS function was satisfactory in this patient
with an indexed EOA (iEOA) of 1.01 and a mean gradient of
11.5 mmHg. The aortic dimensions for the annulus, aortic sinus,
STJ and ascending aorta were 19, 22.5, 20 and 28 mm, respectively.
After 1 month, the transvalvular gradients had slightly increased
to 31/16 mmHg, and the iEOA had decreased to 0.89. One
year later, all cusps showed evidence of degeneration with a
transvalvular leak between the RCC/NCC and eccentric jets
(mild-to-moderate regurgitation). Another 6 months later, all
three leaﬂets degenerated severely and showed limited or absent
(RCC) movements with gradients of 98/66 mmHg and an iEOA
of 0.32, graded as severe stenosis (and moderate-to-severe
regurgitation; Fig. 3). The cause was judged intraoperatively to be
folding of the RCC and NCCs due to oversizing, with signs of
diffuse degeneration. Post hoc, the cusp areas for NCC, LCC and
RCC after 12 and 20 months were found to be 1.01 (1.07) cm2,
1.09 (1.08) cm2 and 1.34 (1.26) cm2, respectively.
Case 3. The patient underwent AVR because of severe aortic
regurgitation, with a dilated and hypertrophic left ventricle
[left ventricular enddiastolic diameter (LVEDD) 64 mm] and
cardiomyopathy (EF 15%). The diameters for the annulus, aortic
sinus, STJ and ascending aorta were 33, 43, 38 and 40 mm,
respectively. The patient was discharged 7 days after AVR with
improved EF (25%), in sinus rhythm, with competent valve function
with a mean gradient of 14 mmHg. Aortic regurgitation was ﬁrst
noted 2 months later, and was further classiﬁed as moderate and then
severe after 5 and 8 months, respectively. The regurgitation fraction
increased from 36 to 53 and 70%, and the corresponding LVEDD
increased to 68 and 76 mm, respectively. At reoperation, the valve was
found to be normal and the aortic STJ further dilated (44 mm).
Case 4. After combined CABG and AVR, close observation
was advised as there was some evidence of mild-to-moderate
regurgitation and gradients of 43/25 mmHg at discharge.
Nonetheless, the follow-up investigation 2 years later showed
severe regurgitation combined with functional stenosis (gradients
88/44 mmHg, Vmax 4.7 m/s, pressure half time (PHT) 214 ms and
EOA 2.2 cm2). At reoperation, the NCC was found completely
dehiscent from the annulus with paravalvular leakage. There were
no histological signs of degenerative valve changes.
Case 5. The patient caught a cold someweeks after uncomplicated
AVR and declined physically after unsuccessful treatment with
antibiotics. Coagulase-negative staphylococci were detected in 4/4
blood cultures. When infective endocarditis with vegetation was
conﬁrmed intraoperatively, the valve replaced uneventfully.
Prosthesis replacement due to structural valve
deterioration
Leaﬂet tears. Four male patients with initially uneventful AVR (FS
sizes 27 [n = 3] and 25 [n = 1]) all presented with acute dyspnoea,
cardiac failure and severe aortic regurgitation after a mean of
6.2 years (4.6–7.3 years). Importantly, each case featured a sharp
vertical tear along the NCC/RCC commissure to the base (Fig. 4).
No valve showed any evidence of endocarditis, and aortic
dimensions were normal at all times.
Case 6. Gradients after AVR were 11.7/6.6 mmHg with an EOA
of 2.54 cm2. Intercommissural distances were 27.2 mm (NCC),
26.2 mm (LCC) and 27.4 mm (RCC) in the post hoc analysis. The
patient was re-admitted after 4.6 years with acute cardiac failure
and underwent urgent reoperation. A sharp and vertical tear in
the RCC was found just next to the NCC/RCC commissure.
Case 7. The patient was re-admitted with acute aortic regurgitation.
A sharp tear of the NCC next to the NCC/RCC commissure was
found intraoperatively (Fig. 4A).
Case 8. The patient was re-admitted with acute severe aortic
regurgitation (PHT: 110 ms) and moderate mitral regurgitation. Again,
a sharp tear of the NCC next to the NCC/RCC commissure was
found intraoperatively (Fig. 4B). The prosthesis was replaced in the
course with mitral valve repair/replacement and CABG. Redundant
intramural haematoma necessitated concomitant tube replacement
of the ascending aorta. Despite the extensive procedure, the patient
recovered well and was discharged on the 10th postoperative day.
Figure 1: Kaplan–Meier estimates for death, explantation and structural valve
degeneration.
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Case 9. Light-to-moderate sclerosis was ﬁrst recorded 3 years
after AVR in a fully competent valve. There was no increase
of gradients in subsequent controls, and the patient was well
and active until he felt a sudden decrease in physical capacity. A
vertical tear in the NCC was found just next to the NCC/LCC
commissure, together with a severely restricted RCC movement.
Degeneration and severe calciﬁcation. Four female patients
required explantation of the FS after a mean of 7.6 years (7.0–8.3
years) due to severe calciﬁcation and functional stenosis (Fig. 5). All
FS valves were very difﬁcult to replace and in each case a stented
valve at least one size smaller was used. It is important to note that
annulus shrinkage and gross calciﬁcation always included the aortic
root. Cusps consistently showed a dull matt and rough ventricular
surface and a glossy smooth sclerotic aortic surface (Fig. 5E).
Case 10. The patient had previously received a CABG and
underwent uneventful AVR as a redo procedure. The valve
prosthesis developed severe stenosis (EOA 0.3 cm2, Fig. 5A) 7.2
years later and was replaced after extensive decalciﬁcation and
root enlargement with a stented valve (size 19).
Case 11. Early postoperative gradients following AVR were
18/10 mmHg. They remained stable until they began to increase
Table 2: Case series
Case Sex, age (years)
at AVR
Indication FS Explant after
(years)
Symptoms New
prosthesis
Concomitant
procedure
Cause Discharge
1 F, 76 AS #27 0.4 Moderate
AR
#23 PM Thrombus (NCC) Dead
2 F, 62 AS #23 1.8 Severe
AR + AS
#21 PM Root enlargement Oversizing, degeneration Alive
3 F, 65 AR #27 1.0 Severe AR #25 PM Dilated STJ Alive
4 F, 70 AR #23 1.9 Severe
AR + AS
#23 PM NCC dehiscence Alive
5 C, 75 AS #27 0.2 Moderate
AR
#25 PM Abscess patch Endocarditis Alive
6 F, 69 AS #27 4.3 Severe AR #25 PM Vertical tear (RCC) near
commissure
Alive
7 F, 64 AS #27 6.4 Severe AR #25 PM Vertical tear (NCC) near
commissure
Alive
8 F, 54 BAV, AR #27 6.2 Severe AR #23 PM MVR, CABG, TVR Vertical tear (NCC) near
commissure
Alive
9 F, 76 AS #25 7.3 Severe AR #21 PM Vertical tear (NCC) near
commissure
Alive
10 C, 63 AS #19 7.2 Severe AS #19 PM Root enlargement Calcification Alive
11 C, 60 AR/AS #23 7.9 Severe AS #20 ATS Calcification Alive
12 C, 66 AS #23 8.3 Severe AS #21 PM Calcification Alive
13 C, 56 AS #21 7.0 Severe AS #19 PM ECMO, TVR Calcification Dead
14 F, 62 AR/AS #23 7.0 Severe AS #21 PM CABG Calcification Alive
AR: aortic regurgitation; AS: aortic stenosis; BAV: bicuspid aortic valve; RCC: right coronary cusp; CABG: coronary arterial bypass grafting; NCC: non-coronary
cusp; TVR: tricuspid valve repair (replacement); MVR: mitral valve repair (replacement); STJ: sinotubular junction; ECMO: extracorporeal membrane
oxygenation; PM: Perimount; FS: freedom SOLO.
Figure 2: Immobile non-coronary cusp due to thrombus formation on the leaﬂet (Case 1).
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notably in the ﬁfth postoperative year. Despite severe COPD (Gold
IV), the patient underwent reoperation because of rapid physical
decline, an EOA of 0.45 cm2 and elevated pulmonary pressures.
All cusps were found immobile and were severely calciﬁed with a
rough ventricular surface and smooth sclerotic aortic surface. The
replacement required extensive and aggressive decalciﬁcation
(Fig. 5B and C).
Case 12. Gradients in this patient were 14/8 mmHg after AVR, but
began to increase in the second postoperative year. The severely
stenotic prosthesis (EOA 0.3 cm2) was replaced after extensive
decalciﬁcation (Fig. 5D) with a stented prosthesis two sizes smaller.
Case 13. The patient underwent AVR with early postoperative
gradients of 11/5 mmHg that increased continually to 84/49 mmHg
in the seventh postoperative year with an EOA of 0.3 cm2. All cusps
were found to be completely immobile. The prosthesis was replaced
with great difﬁculty due to a shrunken and grossly calciﬁed root. The
case was complicated by right ventricular failure, ECMO and
tricuspid valve repair, so that the patient eventually failed to survive.
Case 14. The patient noted progressive dyspnoea and decline in
physical capacity. TOE showed stiff leaﬂets and a completely
immobile RCC, with a partly fused NCC/LCC commissure (3.4 mm
length) and a gradient at rest of 57/28 mmHg. Post hoc analysis of
the TOE records showed intercommissural distances before and
after commissure fusion of 17.3 mm (13.9 mm, NCC), 15.4 mm
(13.2 mm, LCC) and 15.2 mm (15.2 mm, RCC), respectively.
Histology
On histological examination, the explanted valves with macroscopic
sclerosis revealed extensive, band-like calciﬁcation within the central
part of the prosthesis, accompanied in general by moderate ﬁbrosis
on either side (Fig. 6). Foreign body reactions, relevant inﬂammation,
necrosis and bacterial colonization in the setting of infectious endo-
carditis were not found. Neither relevant mononuclear (macro-
phages or lymphocytes) nor polymorphonuclear inﬁltrates were
observed in any of the explanted valves. The explanted leaﬂets com-
monly showed a rough ventricular surface with microscopic tears in
some specimen (Figs 5E and 6). The valves with macroscopically
visible tears showed no further pathology, and in particular no prom-
inent inﬂammatory inﬁltrate within the area of the tear. Neointima
formation, if present, was minimal.
Figure 3: Echocardiography showing a Freedom SOLO valve in systole (A) and diastole (B). Twenty-one months after aortic valve replacement (Case 2).
Figure 4: Tear of Freedom SOLO with acute regurgitation at NCC/RCC commissure. Case 7 (A) and Case 8 (B). NCC: non-coronary cusp; RCC: right coronary cusp;
LCC: left coronary cusp.
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DISCUSSION
We report 14 cases of prosthesis explantation due to structural
(n = 9) and non-structural (n = 5) valve failure among 149 con-
secutive patients who received an FS stentless valve. In all cases of
non-sclerotic SVD, acute vertical tears of the NCC were located in
close proximity commissure, and in our series they occurred, on
average, 1.5 years (6.0 vs 7.5 years) earlier than explantation for
degenerative stenosis. Calciﬁcation was always strikingly severe
and included the entire aortic root.
Figure 5: Sclerosis and decalciﬁcation. NCC: non-coronary cusp; RCC: right coronary cusp; LCC: left coronary cusp.
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Though it is usually easy to determine the correct valve size,
when the manufacturer’s recommendations are followed, there
can be tough cases. When in doubt, one should consider that
oversizing the FS (and other stentless valves) may result in
S-shaped leaﬂet folding with functional stenosis and high gradi-
ents [8]. Another source of dysfunction can be the presence or
likelihood of future root and/or STJ dilatation with the potential to
cause regurgitation [9]. The FS features redundant leaﬂet tissue for
a relatively large coaptation area that compensates for mismatches
at the sinotubular ridge during diastole and thus provides greater
tolerance to STJ dilatation when compared with other stentless
valves [8]. This means that both oversizing and undersizing (par-
ticularly in combination with root dilatation) have the potential to
cause prosthesis failure. Asymmetric implantation will cause the
valve to become distorted with eccentric regurgitation, potentially
resulting in increased chronic mechanical stress and premature
valve deterioration. Symmetric implantation, however, may be dif-
ﬁcult in bicuspid aortic valves (BAVs) when the commissure land-
mark is missing. There is also a potential risk of regurgitation over
time due to presumed co-existent aortic disease and potentially
progressive aortic dilatation in these patients. The use of FS should
therefore be restrictive in patients with a BAV and an enlarged
aorta. In consequence, the observation of root anatomy, correct
sizing and symmetric implantation must be given particular atten-
tion. Another potential pitfall is associated with the implantation
technique that uses three equidistant, intercommissural sutures at
the nadir of each sinus that are placed at the corresponding part
of the prosthetic cusps, using the pericardial strip available at the
basis of the stentless valve. This technique ﬁrmly ﬁxes the pros-
thesis to the aortic wall and deep bites into the aorta are necessary
for permanent attachment. Particularly in the early phase of the
learning curve, there might be reluctance to avoid too small
suture bites and to judge the necessary aortic wall elasticity
required for safe implantation. This could potentially explain the
paravalvular leakage due to the dehiscent NCC in Case 4 or in the
absence of any signs of prosthesis degeneration.
Four cases had presented with acute regurgitation due to verti-
cal leaﬂet rupture. It is important to note that only the large size
25 and 27 prostheses were affected in our series, while it is strik-
ingly that all tears were located in close proximity to the NCC/
RCC or NCC/LCC commissure.
Due to their unrestricted design, stentless valves are fully
exposed to the interaction between aortic root dynamics and
valve mechanics. A ﬂexible aortic root is thought to be essential
for natural leaﬂet stress distribution. It was thus hypothesized that
implantation of an unstented xenograft in a subcoronary, scal-
loped fashion that minimally disrupts aortic root dynamics would
reduce dynamic stress on leaﬂets, translating into a lower prob-
ability of SVD [10]. In fact, however, the aortic root undergoes
complex, asymmetric deformations during the various phases of
the cardiac cycle, including aorto-ventricular and sinotubular
strain and aortic root elongation, compression, shear and torsional
deformation [10]. These deformations are not homogeneous for
the three sinuses. The NCC sinus is usually larger with corres-
ponding volume, height, width, leaﬂet size and thickness [11].
Consequently, the NC intercommissural length was found to
undergo signiﬁcantly more expansion (compared with the right
and left intercommissural lengths) during the cardiac cycle [12],
associated with peak stresses that are located at the free margin
and belly near the coaptation surfaces [11]. In the sheep model,
deformations at the STJ were symmetric and uniform, whereas
there is heterogeneous shear and torsion deformation of the
aortic root during the cardiac cycle, that is, one sinus twisting in
the opposite direction than the other two [10]. Importantly, the
LCC and NCC sinuses were found to undergo clockwise torsion,
whereas the right sinus undergoes counterclockwise torsion
during the ejection phase [10]. This puts stress on the NCC/RCC
commissure and could explain why we only saw tears close to this
particular location.
Caprili et al. reported a grossly calciﬁed FS bioprosthesis that
was replaced 18 months after the initial AVR. The authors sug-
gested that, in this particular case, the positioning and symmetry
in a dilated aorta (37.5 mm) could not be achieved perfectly.
This could have led to increased mechanical stress on the cusps,
accelerating mineralization [13]. In our series of 4 cases, gross cal-
ciﬁcation of the prostheses involved the whole aortic root in-
cluding a shrunken and immobile annulus. Whereas a compliant
aortic root contributes substantially to smooth and symmetrical
leaﬂet opening with minimal gradients, this effect is strikingly
absent with stiff roots and contributes to premature SVD [14].
Furthermore, the severe calciﬁcation and adhesions between the
subcoronary stentless valve and the native aortic wall may require
extensive dissection with the risk of damage to the coronary ostia,
aortic wall and annulus. Unlike stented prostheses, the FS is
attached directly to the aortic wall (with 5 mm of the pericardial
sheet), potentially allowing chemical valve compounds to interact
with aortic endothelial cells.
All biological tissue valves including the FS primarily undergo
chemical ﬁxation with GA to provide mechanical stability, at the
Figure 6: Two examples of degenerated valve prosthesis (haematoxylin and
eosin staining). (A) A band-like calciﬁcation within the central portion of the
valve (white arrows). Minimal ﬁbrin and platelet deposits are noted focally on
the surface (black arrow). (B) A similar picture, although less calciﬁcation is
observed (white arrow) and more dense ﬁbrosis/sclerosis can be noted (black
star). Absence of inﬂammatory inﬁltrates and neovascularization.
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expense of susceptibility to calciﬁcation [15]. In a unique treat-
ment, Sorin uses HCA featuring strong electronegative sulphonic
groups as post-ﬁxation treatment bonding to neutralize free toxic
aldehyde groups in the FS valve [16, 17]. In a subcutaneous rat
model, GA–HCA-treated bovine pericardium showed less calciﬁ-
cation than GA alone after explantation (14–84 days) [16]. The ef-
fectiveness, however, has been questioned because this model
ignores mechanical and dynamic stress or blood-surface contact
[18]. In fact, results from the subcutaneous rat model were the
exact opposite of those from the blood contact and the pulsatile
models, emphasizing the necessity of blood contact in preclinical
valve testing [18].
Prostheses with tears and cusp ruptures were relatively easy to
replace. In contrast, cases with severe calciﬁcation turned out to
require very difﬁcult and demanding reoperations. FS valves were
replaced with prostheses at least one size smaller than the FS,
and it must be expected that root replacement will be necessary.
Our experience is in agreement with a previous report that reo-
perations after stentless AVR are challenging, more complex
procedures associated with increased operative risk compared
with a redo AVR after implantation of other valve prostheses [4].
Alternatively, transcatheter heart valve aortic valve-in-valve implant-
ation is likely to become increasingly important for the treatment of
patients considered high risk or inoperable with degenerated and
failing FS stentless bioprostheses. Despite the presumed hazards of
ostial coronary obstruction, risk estimation and careful planning of
the procedure are possible due to the known location and effective
height of leaﬂets and following the determination of coronary ostia
location [19].
The freedom from explantation for SVD in our cohort is 0.84
[0.70–0.92] and 0.76 [0.50–0.89] after 8 and 9 years, respectively,
comparable with similar data reported for the Toronto [20]
and Biocor [21] stentless valves. However, after 10 years, the
freedom from SVD and reoperation dropped dramatically in
earlier porcine models, such as the O’Brien (CryoLife, Atlanta,
GA, USA) [22], Shelhigh (Shelhigh, Inc., Millburn, NJ, USA) [23],
Biocor (St. Jude Medical, St. Paul, MN, USA) [21] and the Toronto
SPV (St. Jude Medical, St. Paul, MN, USA) [20]. As a critical obser-
vation period now approaches, additional data from other
centres will help to determine the FS long-term durability of the
FS prosthesis and the concept of current third-generation stent-
less valves.
Limitations
This single-centre study shares the limitation of representing a se-
lection of patients. Due to the advanced age in this typical cohort
of patients undergoing AVR, a substantial number of patients did
not reach the full observation time and died for reasons we are
not always able to identify clearly. The true incidence of prema-
ture prosthesis failure may therefore be underestimated.
Furthermore, some patients did develop relevant SVD, but
declined surgical treatment. These valves were not available for
analysis and thus cases that would have added to our understand-
ing may have been missed. We introduced the FS particularly
early after it had become available and our institution provided
training and proctoring. Thus, information about design-related
limitations was largely unavailable at the outset, and learning
curves may have played a role. Because we report a case series
from a single centre including valve-dependent and -independent
failures, a ﬁnal conclusion on the durability of the FS valve requires
more data and reports on freedom from adverse events from
other institutions.
Conclusions
In contrast to stented valves, stentless valve implantation is less
reproducible and standardized, and requires more surgeon-
dependent experience. The ideal patient has a symmetric aortic
root and a trileaﬂet valve-sinus anatomy. The observation of root
anatomy, correct sizing and symmetric implantation must be given
particular attention, because any malpositioning can lead to tissue
fatigue over time leading to SVD. The potential for better outcomes
depends on optimal patient selection and observance of the limita-
tions for the use of the FS. This case series of prosthesis explantation
due to structural and non-structural valve dysfunction allows some
recommendations for use. Both oversizing and undersizing have the
potential to cause prosthesis failure. Furthermore, the use of FS
should be restrictive in patients with BAV because of the missing
commissure landmark and co-existing aortic wall pathology, as well
as in enlarged aortas. Deep suture bites are necessary for safe at-
tachment of the FS, depending, in part, on the aortic wall quality. A
thinned and frail aorta and massive calciﬁcation of the aortic sinus
wall and root are incompatible with FS.
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